Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 14, 2018

View Archived Issues

Phase I safety data reported for cannabinoid therapy in drug-resistant pediatric epilepsy

Discovery of the oncological action of the long non-coding RNA, THOR, in renal cell carcinoma

Development of riluzole prodrugs for the treatment of amyotrophic lateral sclerosis

Biomarkers to identify candidates for CAR T-cell immunotherapy

Discovery of a novel enzymatic function of histone deacetylase 11

Tightening pores fights prostate cancer

Kidney cancer grows up, too

PIM-2 kinase suppresses T-cell responses to alloantigen and tumor cells

Cellect signs stem cell collaboration agreement with Cell2in

First patient treated in phase Ib study of resiniferatoxin for OA knee pain

VistaGen and Baylor College of Medicine collaborate on first-step study of AV-101

OrthoTrophix presents phase II results for TPX-100 in patients with knee osteoarthritis

FDA issues complete response letter regarding the sBLA for Eylea

Liverpool School of Tropical Medicine and collaborators patent compounds for filariasis

Mustang Bio, St. Jude's Children's Research Hospital to develop gene therapy for X-SCID

Council of Scientific and Industrial Research divulges caerulomycin A analogues

New Janus kinase inhibitors synthesized at Leo Pharma

REVOLUTION Medicines discovers SHP-2 inhibitors

Sunshine Lake Pharma presents acetyl-CoA carboxylase inhibitors

Illuminating the Black Box: Mechanism identified for thalidomide teratogenicity

Izana Bioscience begins phase II proof-of-concept study of namilumab in ankylosing spondylitis

Unum Therapeutics preparing phase I trial of ACTR T cells plus trastuzumab

Bayer, Haplogen to identify antiviral compounds for COPD exacerbations

The Leukemia & Lymphoma Society and Sutro Biopharma partner to develop STRO-001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...